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Abstract
Background: Maintenance treatment with antidepressants is the leading strategy to prevent relapse and
recurrence in patients with recurrent major depressive disorder (MDD) who have responded to acute treatment
with antidepressants (AD). However, in clinical practice most patients (up to 70-80%) are not willing to take this
medication after remission or take too low dosages. Moreover, as patients need to take medication for several
years, it may not be the most cost-effective strategy. The best established effective and available alternative is brief
cognitive therapy (CT). However, it is unclear whether brief CT while tapering antidepressants (AD) is an effective
alternative for long term use of AD in recurrent depression. In addition, it is unclear whether the combination of
AD to brief CT is beneficial.
Methods/design: Therefore, we will compare the effectiveness and cost-effectiveness of brief CT while tapering
AD to maintenance AD and the combination of CT with maintenance AD. In addition, we examine whether the
prophylactic effect of CT was due to CT tackling illness related risk factors for recurrence such as residual
symptoms or to its efficacy to modify presumed vulnerability factors of recurrence (e.g. rigid explicit and/or implicit
dysfunctional attitudes). This is a multicenter RCT comparing the above treatment scenarios. Remitted patients on
AD with at least two previous depressive episodes in the past five years (n = 276) will be recruited. The primary
outcome is time related proportion of depression relapse/recurrence during minimal 15 months using DSM-IV-R
criteria as assessed by the Structural Clinical Interview for Depression. Secondary outcome: economic evaluation
(using a societal perspective) and number, duration and severity of relapses/recurrences.
Discussion: This will be the first trial to investigate whether CT is effective in preventing relapse to depression in
recurrent depression while tapering antidepressant treatment compared to antidepressant treatment alone and the
combination of both. In addition, we explore explicit and implicit mediators of CT.
Trial registration: Netherlands Trial Register (NTR): NTR1907
Background
Major depressive disorder (MDD) is projected to rank
second on a list of 15 major diseases in terms of burden
of disease in 2030 [1]. The major contribution of MDD
to disability and health care costs is largely due to its
highly recurrent nature [2,3]. Accordingly, efforts to
reduce the disabling effects of depression should shift to
preventing recurrences, especially in patients at high
risk of recurrence. Several international guidelines (e.g.,
[4,5]) report that patients remitted from prior depressive
episodes belong to such high risk groups. The preven-
tive strategy globally suggested, i.e. continuation of anti-
depressants (AD) for years, is certainly not in line with
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the fact that 70-80% of the patients are not willing to
take AD for a long period of time [6,7]. Many patients
prefer psychological interventions instead. Moreover,
continuation of AD has clear limitations. First, non-
adherence in AD-users is common (50%, [5-8]). It may
also be contraindicated because of somatic illness or
side effects. Further, patients’ protection from recur-
rence ceases on discontinuation of AD [9]. Moreover, a
recent meta-analysis indicates that with increasing num-
ber of previous episodes, patients develop resistance
against the prophylactic properties of AD [10]. Finally,
the optimal duration of the maintenance phase has not
been studied adequately since few studies reported fol-
low-up periods longer than 1 year.
Meta-analyses indicate that cognitive therapy (CT) is
not only an effective treatment of MDD, but can also be
used as an effective preventive intervention [10-17].
Sequential treatment in which CT is started after remis-
sion has proven to be effective in preventing recurrences
in patients with recurrent MDD (e.g. for a meta-analysis
see [12]). In a previous multicenter RCT enrolling
remitted recurrently depressed patients, the efficacy and
cost-effectiveness of CT was evaluated added to treat-
ment as usual (TAU) compared with TAU alone [18].
In line with other studies on this preventive CT,
CT was effective [6] and cost-effective [Bockting
CLH, Dijkgraaf MGW, Hakaart-van Roijen L et al. Cost-
effectiveness of relapse-prevention cognitive therapy in
recurrent depression: a two year study. Submitted] in
preventing recurrences over a 2-year follow-up and also
over 5.5 years in patients with multiple previous epi-
sodes [19]. In this case TAU included several types of
aftercare; e.g. continuation of AD, non-controlled taper-
ing and discontinuation of AD, both in primary and sec-
ondary care. Recently, the preventive effects of CT in
primary care have been confirmed in patients who have
experienced multiple previous episodes [20]. Since in
our prior studies we did not plan a controlled tapering
of AD treatment versus AD continuation or the combi-
nation with CT, we could not examine whether CT
while tapering AD or combining it with AD is an effec-
tive strategy in preventing relapse in recurrent depres-
sion [5,21]. A previous study [22] randomly assigning
remitted recurrently depressed patients (n = 40) to CT
or clinical management, while withdrawing AD, reported
a 50% reduction in relapse rate in CT vs. clinical man-
agement over 6-year follow-up (40% vs. 90%). This
study suggests long term effects of CT in patients that
stopped AD. There is convincing evidence, based on a
recent meta-analysis [12], for the preventive effect of
CT, and some evidence for specific forms of CT (like
Mindfulness Based Cognitive Therapy; MBCT). In the
UK a recent study (n = 123) compared CT (MBCT)
while tapering AD, against AD in recurrent depression
and revealed relapse rates over 1 year of 47% for CT
while 60% of the patients relapse in the group that used
AD [23].
Trial objectives and Purpose
The objective of this study is to examine whether CT is
an effective preventive strategy in reducing relapse/
recurrence while tapering AD compared to continua-
tion of AD versus the combination of maintenance AD
with CT.
Alongside this effect study an economic evaluation
will be performed. In addition, the study explores poten-
tial moderators to examine what works for whom.
Potential mediators will be examined to explore the
working mechanism of preventive CT by assessing
implicit and explicit beliefs, coping related factors,
symptoms, stressful life events, and their association to
risk of relapse to depression, before, between and after
treatment and during the follow-up period.
Methods/Design
In this multi-center randomized controlled three-arm
trial with a sample size of 276 participants an 8 session
group CT with guided tapering of AD, will be compared
to continuation of maintenance AD use versus the com-
bination of CT with maintenance AD in remitted
patients with recurrent MDD. In doing so we stratify on
the number of previous episodes and type of aftercare.
The effectiveness and cost-effectiveness (societal per-
spective) of the interventions will be examined with a
follow-up of minimal 15 months.
We undertake randomization by telephone to the Psy-
chiatry department of the University Medical Center of
Groningen (UMCG). The number of previous depressive
episodes and type of care are delineated for stratification
reasons.
We monitor the primary outcome (relapse) over a
period of minimal 15 months. Assessments by trained
assessors who are blind to treatment allocation (and
whose blindness is checked within each assessment ses-
sion) take place directly after the start of the treatment,
at three months, nine and 15 months. In between there
is additionally a self report assessment at 1.5 months for
the research question on mediation. For an overview of
the study’s procedure see Figure 1.
The interventions
CT-arms
Patients in the two arms including CT (with tapering of
AD and with continuation of AD) receive the proposed
intervention (8 weekly group sessions). CT helps
patients to identify and change presumed vulnerability
factors of recurrence, i.e. dysfunctional beliefs, in line
with traditional CT in the acute phase of depression.
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Traditional CT assumes that change of the negative
content of thoughts and attitudes are crucial features of
successful interventions. More recent cognitive theories
of depression, however, emphasize the role of informa-
tion-processing biases and suggest that these biases are
at the core of depression vulnerability and enhanced
stress reactivity, via enhancing the elaboration of nega-
tive material in memory and reasoning (e.g. [24]). If
indeed a difficulty to disengage from negative material is
critically involved in the return of complaints, it would
Yes 
Recruitment by media attention and posters, through recruitment in general 
practitioners and secondary mental health care centers, i.e. they are asked 
to refer eligible participants by providing the study’s information letter 
including response form and informed consent 
Interested individuals reply to the information letter, or by the study’s 
telephone number or e-mail address (media). 
Researchers globally screen participants willing to participate by telephone 
for inclusion and exclusion criteria (and sends information and a written 
consent form if participant responded through media) 
Does the participant meet 
screening criteria and is willing 
to provide informed consent? 
Trained researcher checks whether informed consent is received and 
answers remaining questions. Afterwards appointment for pre-treatment 
SCID-I interview and HDRS by telephone is made to determine whether 
participant meets study inclusion criteria. 
Does the participant meet full 
inclusion criteria? 
Participant is randomized 
Stratified by number of previous depressive episodes and type of care
AD 
continued 
AD + PCT PCT  
alone 
No Exclude 
No Exclude 
Yes 
Pre-treatment measures T0
Assessments during treatment (T1; 6 weeks) and after treatment at 3, 6, 9, 12 
and 15 months. 
Figure 1 Flow-chart of the study. AD = antidepressant, PCT = preventive cognitive therapy.
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be important to see whether CT is not only successful
in changing content of thoughts and memory associa-
tions, but also helps to increase inhibitory control,
thereby disrupting the processes of negative emotions
and ruminative negative thinking patterns [25].
AD-arms
In the treatment arms where AD will be continued, GP’s
and psychiatrists will be advised to continue AD prescrip-
tion at minimal required adequate used dosage (≥ 20 mg
Fluoxetine equivalent; [6] as recommended by national
guidelines [26]. In the treatment arm including guided
tapering of AD GP’s and psychiatrists will be advised to
taper AD in 4 weeks to prevent withdrawal symptoms. In
this arm patients will be asked for an intention to taper
AD. The patient is allowed to start AD again at any time
during the study (this will be monitored).
We will assess compliance and adherence to AD use
with the Medication Adherence Scale [27]. We also
assess adherence to CT prescription of homework and
presence at the sessions. Patients will be encouraged to
use medication/do homework as prescribed and doc-
tors/psychiatrists will be encouraged to prescribe thera-
peutic dosages, as well as discuss problems with
adherence frequently.
Sample size
In total 276 patients will be recruited. This sample size
provides 80% power (alpha 0.05, two sided) to demon-
strate in survival analysis a clinical significant difference
of 20% in relapse/recurrence between AD versus
AD+CT (relapse 50% in AD patients versus 30% in
AD+CT) patients after 15 months, based on a recent
meta-analysis on AD versus placebo [10]. Taking into
account 15% attrition, for this comparison 2 × 98 parti-
cipants will be needed. To demonstrate a clinically sig-
nificant difference of 15% in relapse/recurrence rate
(relapse rate AD: 50%) between the two treatment arms
with continuation of AD versus the CT arm while taper-
ing continuation AD additional 80 participants will be
needed.
Inclusion criteria
We will include patients:
-with at least two previous depressive episodes in the
past five years.
-who are currently in remission according to DSM-IV
criteria, for longer than 8 weeks and no longer than
2 years.
-that have a current score of <10 in the 17 item
Hamilton Rating Scale for Depression (HRSD; in line
with other prevention studies, e.g. [12,18,28]
-for whom the last episode is at least 2 months and no
longer than 2 years ago.
-that have been remitted on antidepressant treatment
and use AD at entry in the study (delivered in primary
or secondary care) for at least 6 months.
Exclusion criteria
Exclusion criteria are: current mania or hypomania or a
history of bipolar illness, any psychotic disorder (current
and previous), organic brain damage, alcohol or drug
dependency/abuse, predominant anxiety disorder.
Eligibility, informed consent and baseline assessments
The target population is a high-risk group as identified
in several guidelines, (e.g., [4,5]) that consumes a con-
siderable amount of health care and for whom initial
benefits of AD may be lost in the long run. Relapse
rates rise with increasing numbers of previous episodes
up to 70% in 5 years [28]. In our previous study, we
observed up to 62% recurrences within 2 years [29].
A highly similar recruitment procedure will be used as
in our previous study in which we recruited via media
and via referrals from general practitioners or medical
specialists in secondary mental health care [18,19]. The
study will be conducted by a team of clinical psycholo-
gists of the department of Psychology at the University
of Groningen in collaboration with psychologists of the
Rotterdam University and Maastricht University and
psychiatrists of the departments of Psychiatry of the
University of Amsterdam (AMC) and the Groningen
University (UMCG). We collaborate with 16 mental
health care sites in The Netherlands. The group inter-
vention will be performed in several cities. Therapists of
the sites will be trained with a CT manual to promote
treatment integrity.
Informed consent
We inform patients about the study before they come
into the study in two ways. First, by informing the
patient through their therapist: if a therapist wants to
inform the patient themselves, the patient then
receives the information via the therapist and is given
a letter containing all the information. If the patient is
interested in participating then the participant contacts
the researcher. Subsequently, the researcher checks
whether the participant understands all aspects of the
trial. If they agree to enter the trial, they complete a
copy of the consent form and send it back to the
researcher.
The second procedure we use is by directly informing
the patient in case the patient contacts the researcher
(mostly informed by media or by their former therapist/
GP with a letter, by advertisements or interviews). Sub-
sequently, the researcher informs the patient, he/she
receives the information in a letter with all the informa-
tion in it. If the patient is still interested in participating
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after reading the information then the participant con-
tacts the researcher. The researcher checks whether the
patient understands all aspects of the trial. If the patient
agrees to enter the trial, he/she completes a copy of the
consent form and sends it to the researcher.
We remind participants that they can withdraw from
the trial at any time and that this will have no conse-
quences for their treatment as usual.
We ask consenting participants to provide information
about their socio-demographic background and assess
their eligibility in more detail using semi-structured
clinical interviews (SCID-I) and self-completed question-
naires. The researchers assess current and past diagnos-
tic status using the Structured Clinical Interview for
DSM-IV (SCID, [30]) and the Hamilton Rating Scale for
Depression (HRSD, [31]). They ask participants to
describe past and current treatments for depression,
their attribution of relapse and recurrence and use of
AD. If participants meet all inclusion and none of the
exclusion criteria for the study, they enter the study.
For the baseline assessment, we ask participants them-
selves to complete the web based self report question-
naires in two packages: explicit and implicit measures.
The first part with assessments starting directly within a
week for the AD continuation only arm, and for the
other arms briefly before starting preventive CT. The sec-
ond part of the assessment include implicit measures that
will be offered within 2 days after completion of the self
report assessments measures. Used self report measures
are: the Inventory of Depressive Symptomatology, IDS-
SR [32], negative life events (Life events questionnaire,
LGV [33], self-esteem (Rosenberg’s Self-esteem Scale
[34]), personality pathology (Personality Diagnostic
Questionnaire, PDQ-4 [35]), somatic complaints (LKV
[36]), everyday problems (EPCL [37]), hypomania
(HCL-32 [38]), direct and indirect costs (TIC-P [39]) and
Medication Adherence Questionnaire (MAQ, [27]). a
measure of general quality of life (Euro-QOL EQ-5 D
[40]), rumination (Ruminative Responses Subscale of the
Response Styles Questionnaire, RSQ [41]), dysfunc-
tional attitudes (Dysfunctional Attitudes Scale, DAS
[42]) and cognitive reactivity using the LEIDS [43]),
acceptance (Acceptance and Action Questionnaire,
AAQ [44]) and coping (Utrecht Coping List, UCL
[45]). After 6 weeks this set will be repeated with the
exception of the TIC-P, LGV, PDQ, MAS and EQ-5 D.
During follow-up every three months the following self
report assessments will be repeated: IDS-SR, HCL-30,
TIC-P, EPCL, and EQ-5 D. For a complete overview of
the assessments see table 1.
Outcome measures
Primary outcome effectiveness: time related proportion
of depression relapse/recurrence in a survival analysis
(Cox regression) over a follow-up period of minimal
15 months using DSM-IV-TR criteria as assessed by
the Structured Clinical Interview for DSM-IV (SCID,
telephonic version, [46]) at 3 months, 9 months and
15 months (current depressive symptomatology and
previous 3 and 6 months).
For potential differential (illness related, stress-related
and cognitive-related) predictors and mediators the fol-
lowing self report measures will be used at baseline, at
1 and at 3 months (internet based): Inventory of Depres-
sive Symptomatology (IDS-SR; [32]), Negative Life
Events Questionnaire [33], Everyday Problem Checklist
(EPCL; [37]), Ruminative Responses Subscale of the
Response Styles Questionnaire (RSQ; [41]), Dysfunc-
tional Attitude Scale, (DAS-A; [42]), LEIDS [43] and to
assess nonadherence to AD with the Medication Adher-
ence Questionnaire (MAQ; [27]). To enable calculating
quality adjusted life years required for the economic
evaluation, also the EQ5 D also will be administered
every 3 months [40]. To test whether CT and/or AD
affect implicit attitudes and attentional bias differentially
and whether residual difficulty to disengage and residual
dysfunctional implicit attitudes are related to the return
of depressive symptoms an Implicit Association Test
(IAT; [47]) that is also used in the Netherlands Study of
Anxiety and Depression http://www.nesda.nl will be
used to assess implicit attitudes. A rapid serial visual
presentation (RSVP; [48]) task will be used to assess the
difficulty to disengage from negative information. Diffi-
culty to disengage will be indexed by the magnitude of
the attentional blink when negative self descriptors are
presented as the first target and neutral words as the
second.
For an overview of the assessments at baseline, in
between- and post treatment and follow up assessments
see table 1.
Withdrawal
Participants can withdraw from treatment or from the
study at any time. Nevertheless we ask those who with-
draw from the trial treatment (CT or CT+AD or AD
alone) if they are willing to attend all the remaining
research appointments or at least to provide minimal
data.
Safety monitoring and reporting
The trial protocol has been approved by an independent
medical ethics committee for all included sites
(METIGG). Eligible people will be included as partici-
pants in the trial only after informed consent has been
obtained.
We record and report suspected serious adverse
events to the Multi-centre Ethic Committee (METIGG)
according to their individual guidelines.
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Analysis
Cox regression analysis (survival analysis) will be per-
formed, including as covariates the stratification vari-
ables that will be used in randomization, and 2
additional variables, i.e.: number of previous episodes,
type of care (primary/secondary). Analysis will be con-
ducted by intention to treat, including all subjects ran-
domized in the study (including dropouts and patients
who did not taper AD), and per protocol, including only
subjects satisfying protocol treatment (up to the point in
the study where they failed to do so). Statistical signifi-
cance will be set at P < .05. Mixed-model analysis will
be used for the other variables, including baseline values
of the dependent variable as a covariate in all analyses.
We shall use stress measures and implicit and explicit
cognitive measures to explore the extent to which they
mediate relapse and recurrence during treatment and
follow up.
For the economic evaluation the balance between
costs and health outcomes will be compared across stra-
tegies using a societal perspective. Primary outcome
measure: the number of depression-free days. Both
short-term and long-term consequences will be com-
pared. Additionally, Quality Adjusted Life Years will be
used as outcome.
Discussion
Recurrent depression is highly prevalent and reducing
relapse and recurrence is therefore essential. This trial
will be the first comparison of CT while tapering AD
versus continuation of AD versus the combination of
both. Apart from the evaluation of the effectiveness and
cost-effectiveness, we examine what works for whom.
The most frequently used preventive strategy, i.e. conti-
nuation of AD for years, is not in line with what
patients do and want (70-80% of the patients are not
willing to take AD long enough; [6,7]). Many patients
prefer psychological interventions instead. The results of
this study might improve better patient by treatment
matching by examining the effects of divers preventive
strategies and explore what strategy is best for a person
with specific characteristics. In addition, mediation
variables will be examined to get more insight into
the essential ingredients of the preventive CT used.
This might lead the development of more targeted
interventions.
In summary, MDD has a highly recurrent nature [2];
accordingly, efforts to reduce the disabling effects of
depression should shift to preventing recurrence, espe-
cially in patients at high risk of recurrence. The develop-
ment and evaluation of alternative preventive strategies
and their specific working mechanism, apart from AD,
are needed to at least disrupt the rhythm of depression
for this large patient group. This trial will contribute to
improved and more efficient therapeutic regimens to
prevent relapse and recurrence in depression.
Appendix 1: Statistical Analysis Plan
The primary outcome measure will be the time to
relapse or recurrence meeting DSM-IV criteria for a
major depressive episode (American Psychiatric Associa-
tion, 1994) on the Structured Clinical Interview for
Table 1 Overview of assessments
Measure Description T0 T1 T2 T3 T4 T5 T6*
IDS-SR Depressive symptoms + + + + + + +
RSQ Ruminative responses + + + +
EQ-5D Quality of life + + + + + +
DAS Dysfunctional Attitudes + + + +
AAQ Experiential acceptance and avoidance + + + +
UCL Coping + + + +
LGV Life-events + + +
Self-esteem Self-esteem + + + +
PDQ-4+ Personality +
LKV Somatic complaints + +
EPCL Everyday problem list + + + + + + +
HCL-32 Hypomania + + + + + + +
TIC-P Direct/indirect costs + + + + + +
LEIDS Dysfunctional attitudes + + + +
SCID-I DSM-IV-TR Axis I disorders + + + +
HDRS Depressive symptoms and severity + + + +
IAT Implicit associations + +
RSVP Ability to disengage from negative information + +
*T0 = Baseline, T1 = ± 1,5 month, T2 = 3 months, T3 = 6 months, T4 = 9 months, T5 = 12 months, T6 = 15 months.
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DSM-IV (SCID, [46]). Occurrence of relapse or recur-
rence (current or since the last assessment point) will be
assessed after treatment at 3 months, and at nine
months and 15 months thereafter by trained psycholo-
gists who are blind to treatment condition. The analysis
will be by ‘intention to treat’ (ITT). The time (in weeks)
of relapse or recurrence to Major Depression, as defined
above, will be the dependent variable in survival analysis.
The treatment group and stratification variables will be
used as predictors.
For participants who are lost from the trial, available
measures will be used and then censored at the time of
their last observation. Since only a participant’s first
relapse or recurrence to Major Depression will contri-
bute to the survival analysis, the subsequent loss of that
participant will not affect the analysis. Participants who
miss one or more follow-up assessments, but are then
assessed at a later time point will be asked about their
current and past symptoms according to SCID diagnos-
tic criteria since their last successful assessment. This
will enable us to assess the time to relapse and thus to
censoring.
In addition, we use Hamilton Rating Scale for Depres-
sion interview (HRSD), to assess the severity of depres-
sion at all time points. The other quantitative measures
used at baseline, before treatment, and every three
months are the IDS-Q, HSRS-E, LKV, PDQ-4, DAS,
LEIDS, UCL, RRS, AAQ-II, Self-esteem questionnaire,
LGV, EPCL, TIC-P and the EQ5-D (used to compute
QALY’s). We shall calculate the ‘area under the curve’
(AUC) of each measure to give a single score.
Mixed-model analysis of covariance (ANCOVA) will
be used for the quantitative measures. As covariates we
shall use the stratification variables (number of episodes
and type of aftercare and treatment group, together with
treatment adherence either to continuation AD or taper-
ing AD or to the number of sessions attended). Potential
moderators to be examined include gender, number of
previous episodes, residual symptoms of depression (e.g.
HRSD score and IDS score at baseline) and duration of
remission, duration of last episode, familial psychiatric
burden, life events (childhood/adult), coping and age of
onset.
For mediation analysis, regression will be used to
examine pre-post change on CT versus AD alone (bin-
ary for the dichotomous outcome of relapse and linear
regression for the HRSD score, the DAS, LEIDS and
daily hassles score (EDPL) during follow-up and the
association of this potential change to outcome (relapse/
recurrence) will be explored.
Cost-effectiveness will be evaluated from a societal
perspective; costs in and outside the healthcare sector
will be part of the analyses. Both short-term and long-
term consequences of the studied interventions will be
taken into account. For the short term analysis, a time
horizon of 15 months will be applied, during which
information on costs and health outcomes will be pro-
spectively collected using the TIC-P. The primary out-
come measure of the cost-effectiveness analysis is the
number of depression-free days as assessed by the SCID.
In the additionally planned cost-utility analysis, QALY’s
(Quality Adjusted Life Years) will be used as the primary
outcome measure as assessed by the EQ5-D. Medical
costs that will be assessed include costs related to CT,
medication use, hospital admissions, and contacts with
healthcare professionals. Outside the healthcare sector,
various costs of informal care and productivity losses
will be included. Unit prices will largely be based on
Dutch standard prices [49]. Costs and health outcomes
will be discounted in accordance with Dutch guidelines.
The bootstrap method will be applied to estimate non-
parametric confidence intervals for mean differences in
costs between groups. Furthermore, cost-effectiveness
acceptability curves will be used to inform decision-
makers on the probability that the studied intervention
is cost-effective. The long-term consequences of CT ver-
sus AD will be addressed by a decision type model,
focusing on a period of 20 years. Main aspects of the
model will be based on data collected in the prospective
part of the trial, literature on the patient population
under study, and expert opinions. Important cost types
that are expected to demonstrate differences between
the two treatment arms over a time frame of 20 years
include costs related to AD use, contacts with healthcare
professionals, and lost productivity. Also, scenario ana-
lyses reflecting the duration of effect will be conducted
to evaluate the period of sustained effect which results
in a break even between costs and long term savings.
The primary health outcome applied in the long-term
model will be the QALY. Since QALY’s cannot directly
be assessed during the 20 years time horizon of the
long-term analysis, previously published data on long-
term QALY outcomes in comparable patient popula-
tions will be used when available (or assumptions will
have to be made). Sensitivity analyses will focus on var-
iations of applied probabilities, QALY estimates, and
influential cost components.
Acknowledgements
The research is funded by ZONMW: The Netherlands association for Health
research and Development (171002401) to CLH Bockting Associate professor
of Clinical Psychology and by ZONMW, The Netherlands association for
Health research and Development, OOG Grant (100002035) to HJ Elgersma
and CLH Bockting. The Netherlands Organization for Scientific Research
(NWO) funded this manuscript.
Author details
1Department of Clinical Psychology, Groningen University, The Netherlands.
2Mental health care center Accare, The Netherlands. 3Department of
Psychiatry, University Medical Center Groningen, Groningen University, The
Bockting et al. BMC Psychiatry 2011, 11:8
http://www.biomedcentral.com/1471-244X/11/8
Page 7 of 9
Netherlands. 4Medical Technology Assessment, Department of Epidemiology,
University Medical Center Groningen, Groningen University, The Netherlands.
5Department of Psychiatry and Neuropsychology, Maastricht University
Medical Center, The Netherlands. 6Department of Clinical Psychological
Science, University of Maastricht, The Netherlands. 7Department of Clinical
and Health Psychology, Erasmus University, Rotterdam, The Netherlands.
8Department of Psychiatry, Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands. 9Vanderbilt University,
Department of Psychology, Nashville, Tennessee, USA.
Authors’ contributions
CB drafted this paper (which was added to and modified by all other
authors) and wrote the treatment manual for the used intervention, WN
wrote the protocol for tapering AD, all authors (except GvR) contributed to
the design of the study and CB and PdJe to the analytic strategy. All authors
read and approved the final manuscript.
Competing interests
CB participated in a discussion on treatment for depression for a web-based
course of Wyeth once on 1/11/2007. FP received speakers’ fees from
GlaxoSmithKline, Wyeth, Astra Zeneca, Lundbeck, Eli Lilly, Servier, and
Janssen-Cilag. WN received grants from Netherlands Organisation for Health
Research and Development, Stanley Medical Research Institute, Astra Zeneca,
Eli Lilly, GlaxoSmithKline and Wyeth, he received speaker’s fees from Astra
Zeneca, Eli Lilly, Pfizer, Servier, Wyeth and was in the advisory board of Astra
Zeneca, Cyberonics, Eli Lilly, GlaxoSmithKline, Pfizer and Servier. All other
authors declare that they have no competing interests.
Received: 10 December 2010 Accepted: 12 January 2011
Published: 12 January 2011
References
1. Mathers CD, Loncar D: Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 2006, 3:442.
2. Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy
and disability-adjusted life expectancy: global Burden of Disease Study.
Lancet 1997, 10(349):1347-52.
3. Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J,
Angermeyer MC, Bromet EJ, Burger H, Demyttenaere K, de Girolamo G,
Haro JM, Hwang I, Karam E, Kawakami N, Lépine JP, Medina-Mora ME,
Posada-Villa J, Sampson N, Scott K, Ustün TB, Von Korff M, Williams DR,
Zhang M, Kessler RC: Disability and treatment of specific mental and
physical disorders across the world: Results from the WHO World Mental
Health Surveys. Br J Psychiatry 2008, 192:368-375.
4. American Psychiatric Association: Practice guidelines for the treatment of
psychiatric disorders: Compendium 2008 Washington, D.C; 2008.
5. Clinical NICE Depression: Management of depression in primary and
secondary care The National Collaborating Centre for Mental Health; 2009.
6. Bockting CLH, ten Doesschate MC, Spijker J, Spinhoven Ph, Schene AH, the
DELTA study group: Continuation and maintenance use of
antidepressants in recurrent depression. Psychoth Psychosom 2008,
77:17-26.
7. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA:
Incidence and determinants of long-term use of antidepressants.
European J Clin Pharmacology 2004, 60:57-61.
8. ten Doesschate MC, Bockting CLH, Schene AH: Adherence to continuation
and maintenance antidepressant use in recurrent depression. J Clin
Psychiatry 2009, 70:63-9.
9. Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant
treatment in major depression. Harv Rev Psychiatry 1998, 5:293-306.
10. Kaymaz N, van Os J, Loonen AJ, Nolen WA: Evidence that patients with
single versus recurrent depressive episodes are differentially sensitive to
treatment discontinuation: a meta-analysis of placebo-controlled
randomized trials. J Clin Psychiatry 2008, 69:1423-36.
11. Beck AT: The current state of cognitive therapy: a 40-year retrospective.
Arch Gen Psychiatry 2005, 62:953-9.
12. Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and
recurrence in unipolar depression: a comparative meta-analysis of
cognitive-behavioral therapy’s effects. J Consult Clin Psychol 2007,
75:475-88.
13. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR,
Salomon RM, O’Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R:
Cognitive Therapy versus Medications in the Treatment of Moderate to
Severe Depression. Arch Gen Psychiatry 2005, 62:409-16.
14. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM,
O’Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R:
Prevention of relapse following cognitive therapy vs medications in
moderate to severe depression. Arch Gen Psychiatry 2005, 62:417-27.
15. Hollon SD, Stewart MO, Strunk D: Enduring effects for cognitive behavior
therapy in the treatment of depression and anxiety. Annu Rev Psychol
2006, 57:285-315.
16. Clarke GN, Hornbrook M, Lynch F, Polen M, Gale J, Beardslee W,
O’Connor E, Seeley J: A randomized trial of a group cognitive
intervention for preventing depression in adolescent offspring of
depressed parents. Archives Gen Psychiatry 2001, 58:1127-34.
17. Dobson KS, Hollon SD, Dimidijan S, Schmaling KB, Kohlenberg RJ, Gallop R,
Rizvi SL, Gollan JK, Dunner DL, Jacobson NS: Randomized trial of
behavioral activation, cognitive therapy, and Antidepressant medication
in prevention of relapse and recurrence in major depression. J Cons Clin
Psychol 2008, 76:468-77.
18. Bockting CLH, Schene AH, Spinhoven Ph, Koeter MWJ, Wouters LF, Huyser J,
Kamphuis JH: Preventing recurrence in recurrent depression using
cognitive therapy. J Cons Clin Psychol 2005, 73:647-657.
19. Bockting CLH, Spinhoven Ph, Koeter MWJ, Schene AH: Long term effects
of preventive cognitive therapy in recurrent depression using: 5.5 years
follow-up. J Clin Psychiatry 2009, 70:1621-8.
20. Conradi HJ, de Jonge P, Ormel J: Differential treatment response in
depressed patients with multiple prior episodes: CT versus the GP;
Cognitive-behavioural therapy v. usual care in recurrent depression.
Br J Psychiatry 2008, 193:505-6.
21. Bockting CLH: The rhythm of depression: The course of recurrent
depression and prevention of relapse using cognitive therapy. PhD thesis
Amsterdam; 2006.
22. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S: Six-year outcome
of cognitive behavior therapy for prevention of recurrent depression.
Am J Psychiatry 2004, 161:1872-1876.
23. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, Barrett B,
Byng R, Evans A, Mullan E, Teasdale JD: Mindfulness-based cognitive
therapy to prevent relapse in recurrent depression. J Consult Clin Psychol
2008, 76:966-978.
24. de Jong PJ, Pasman W, Kindt M, van den Hout MA: A reaction time
paradigm to assess (implicit) complaint-specific dysfunctional beliefs.
Behaviour Res Therapy 2001, 39:101-113.
25. Beevers CG: Cognitive vulnerability to depression: A dual process model.
Clin Psychol Review 2005, 25:975-1002.
26. Multidisciplinary Guidelines (Dutch). Guidelines Depression and Anxiety 2009 .
27. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a
selfreported measure of medication adherence. Med Care 1986, 24:67-74.
28. Ma SH, Teasdale JD: Mindfulness-based cognitive therapy for depression:
Replication and exploration of differential relapse prevention effects.
J Cons Clin Psychol 2004, 72:31-40.
29. Bockting CLH, Spinhoven Ph, Koeter MW, Wouters LF, Schene AH, the
DELTA study group: Prediction of recurrence in recurrent depression and
the influence of consecutive episodes on vulnerability: a 2-year
prospective study. J Clin Psychiatry 2006, 67(5):747-755.
30. Spitzer RL, Williams JBW, Gibbon M, First MB: The Structured Clinical
Interview for DSM-III-R (SCID 1) history, rationale, and description. Arch
Gen Psychiatry 1992, 49(8):624-629.
31. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry
1960, 23:56-62.
32. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inventory of
Depressive Symptomatology (IDS): psychometric properties. Psychol Med
1996, 26:477-86.
33. Kraaij V, De Wilde EJ: Negative life events and depressive symptoms in
the elderly: A life span perspective. Aging and Mental Health 2001,
5:84-91.
34. Franck E, De Raedt R, Barbez C, Rosseel Y: Psychometric properties of the
Dutch Rosenberg self-esteem scale. Pscyhologica Belgica 2008, 48(1):25-35.
35. Akkerhuis GW, Kupka RW, van Groenestijn MAC, Nolen WA: PDQ-4+
Vragenlijst voor persoonlijkheidskenmerken Lisse: Swets & Zeitlinger; 1996.
Bockting et al. BMC Psychiatry 2011, 11:8
http://www.biomedcentral.com/1471-244X/11/8
Page 8 of 9
36. van Hemert AM: Lichamelijke klachten vragenlijst Leids Universitair Medisch
Centrum; 2003.
37. Vingerhoets AJJM, van Tilburg MAL: Everyday Problem Checklist (EPCL) Lisse:
Swets & Zeitlinger B.V; 1994.
38. Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD,
Skeppar P, Vieta E, Scott J: Towards the self-assessment tool for
hypomanic symptoms in outpatients. J Affective Disorders 2005,
88:217-233.
39. Hakkaart-van Roijen L, van Straten A, Donker M, Tiemens B: Handleiding
Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P)
Instituut voor Medische Technology Assessment, Erasmus Universiteit
Rotterdam; 2002.
40. EuroQol Group: EuroQol: a new facility for the measurement of health-
related quality of life. Health Policy 1990, 16:199-208.
41. Treynor W, Gonzalez R, Nolen-Hoeksema S: Rumination reconsidered:
A psychometric analysis. Cogn Therapy Res 2003, 27:247-259.
42. Weissman AN: The Dysfunctional Attitude Scale. Academic dissertation
University of Pennsylvania (Dissertation Abstracts International: 40, 1389B-
1390B); 1979.
43. Van der Does W: Cognitive reactivity to sad mood: structure and validity
of a new measure. Behav Res Ther 2002, 40:105-20.
44. Hayes SC, Strosahl KD, Wilson KG, Bissett RT, Pistorello J, Toarmino D,
Polusny MA, Dykstra TA, Batten SV, Bergan J, Stewart SH, Zvolensky MJ,
Eifert GH, Bond FW, Forsyth JP, Karekla M, Curry SM: Measuring
Experiential Avoidance: A preliminary test of a working model. Psychol
Record 2004, 54(4):553-578.
45. Schreurs PJG, Willige van den G, Brosschot JF, Tellegen B, Graus GMH:
Herziene handleiding De Utrechtse Coping Lijst: UCL. Omgaan met problemen
en gebeurtenissen Lisse: Swes & Zeitlinger; 1993.
46. First MB, Gibbon M, Spitzer RL, Williams JBW: User Guide for the
Structured Clinical Interview for DSM-IV Axis 1 Disorders. Washington,
DC: American Psychiatric Association; 1996.
47. Greenwald AG, McGhee DE, Schwartz JLK: Measuring individual
differences in implicit cognition. The Implicit Association Test.
J Personality Social Psychol 1998, 74:1464-1480.
48. Koster EHW, De Raedt R, Verschuere B, Tibboel H, de Jong PJ: Enhanced
emotioninduced attentional blink for negative information in dysphoria.
Depression and Anxiety 2009, 26:16-22.
49. Oostenbrink JB, Koopmanschap MA, Rutten FFH: Manual for cost studies,
methods and standard prices for economic evaluation in health care [In
Dutch: Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor
economische evaluaties in de gezondheidszorg. Geactualiseerde versie]
Amstelveen: Health Care Insurance Council; 2004.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-244X/11/8/prepub
doi:10.1186/1471-244X-11-8
Cite this article as: Bockting et al.: Disrupting the rhythm of depression:
design and protocol of a randomized controlled trial on preventing
relapse using brief cognitive therapy with or without antidepressants.
BMC Psychiatry 2011 11:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bockting et al. BMC Psychiatry 2011, 11:8
http://www.biomedcentral.com/1471-244X/11/8
Page 9 of 9
